for treating an individual having one or more symptoms of gastritis, enteritis, duodenitis, or gastroenteritis, comprising: (a) detecting number of mast cells from a first sample obtained from gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual; (b) detecting number of eosinophils from a second sample obtained from gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual; and (c) if the first sample has an increased number of mast cells as compared to a mast cell reference and the second sample does not have increased number of eosinophils as compared to an eosinophil reference, administering to the individual an effective amount of a composition comprising an antibody that binds to human Siglec-8.

[0008a] In one aspect, the present disclosure refers to use of a composition comprising an antibody that binds to human sialic acid-binding, immunoglobulin-like lectin 8 (Siglec-8) in the manufacture of a medicament for treating or preventing one or more symptoms of gastritis, enteritis, duodenitis, or gastroenteritis in an individual, wherein the use comprises: (a) detecting number of mast cells from a first sample obtained from gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual; (b) detecting number of eosinophils from a second sample obtained from gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual; and (c) if the first sample has an increased number of mast cells as compared to a mast cell reference and the second sample does not have increased number of eosinophils as compared to an eosinophil reference, an effective amount of the medicament is to be administered to the individual.

[0009] Other examples of the present disclosure relate to methods for treating or preventing one or more symptoms of gastritis, enteritis, duodenitis, or gastroenteritis in an individual comprising administering to the individual an effective amount of a composition comprising an antibody that binds to human Siglec-8, wherein the individual has an increased number of mast cells in at least a portion of the gastric, duodenal, jejunal, ileal, or colonic mucosa as compared to a mast cell reference, and wherein the individual does not have increased number of eosinophils in at least a portion of the gastric, duodenal, jejunal, ileal, or colonic mucosa as compared to an eosinophil reference. Other examples of the present disclosure relate to methods for treating or preventing mast cell gastritis, mast cell enteritis, mast cell duodenitis, or mast cell gastroenteritis in an individual comprising administering to the individual an effective amount of a composition comprising an antibody that binds to human Siglec-8, wherein the individual has an increased number of mast cells in at least a portion of the gastric, duodenal, jejunal, ileal, or colonic mucosa as compared to a mast cell reference, and wherein the individual does not have increased number of eosinophils in at least a portion of the gastric, duodenal, jejunal, ileal, or colonic mucosa as compared to an eosinophil reference. Other examples of the present disclosure relate to methods for treating an individual having one or more symptoms of gastritis, enteritis, duodenitis, or gastroenteritis comprising administering to the individual an effective amount of a composition comprising an antibody that binds to human Siglec-8, wherein the individual has an increased number of mast cells in at least a portion of the gastric, duodenal, jejunal, ileal, or colonic mucosa as compared to a mast cell reference, and wherein the individual does not have increased number of eosinophils in at least a portion of the gastric, duodenal, jejunal, ileal, or colonic mucosa as compared to an eosinophil reference. In some examples, a first sample obtained from the gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual has an increased number of mast cells as compared to the mast cell reference. In some examples, a

examples, the human IgG4 Fc region comprises the amino acid substitution S228P, wherein the amino acid residues are numbered according to the EU index as in Kabat. In some examples, the antibody depletes blood eosinophils and/or inhibits mast cell activation. In some examples, the antibody has been engineered to improve antibody-dependent cell-mediated cytotoxicity (ADCC) activity. In some examples, the antibody comprises at least one amino acid substitution in the Fc region that improves ADCC activity. In some examples, at least one or two of the heavy chains of the antibody is non-fucosylated. In some examples, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:75; and/or a light chain comprising the amino acid sequence selected from SEQ ID NO:76 or 77. In some examples, the antibody is a monoclonal antibody.

[0021] In some examples that may be combined with any other examples described herein, the composition is administered in combination with one or more additional therapeutic agent(s) for treating or preventing gastritis, gastroenteritis, or esophagitis. In some examples, the one or more additional therapeutic agent(s) for treating or preventing gastritis, gastroenteritis, or esophagitis are selected from the group consisting of PPIs, systemic corticosteroids, topical corticosteroids, antihistamines, mast cell stabilizers, H-2 blockers, anti-IgE antibodies, calcineurin inhibitors, immunomodulatory agents, and immunosuppressive agents. In some examples, the individual is a human. In some examples, the composition is a pharmaceutical composition comprising the antibody and a pharmaceutically acceptable carrier.

[0022] Other examples of the present disclosure relate to articles of manufacture or kits comprising a medicament comprising a composition comprising an antibody that binds to human Siglec-8 and a package insert comprising instructions for administration of the medicament in an individual in need thereof according to any one of the above examples. Other examples of the present disclosure relate to articles of manufacture or kits comprising a medicament comprising an antibody that binds to human Siglec-8 and a package insert comprising instructions for administration of the medicament in an individual in need thereof according to any one of the above examples.

[0023] It is to be understood that one, some, or all of the properties of the various examples described herein may be combined to form other examples of the present disclosure. These and other examples of the present disclosure will become apparent to one of skill

CLAIMS

What is claimed is:

1. Use of a composition comprising an antibody that binds to human sialic acid-binding, immunoglobulin-like lectin 8 (Siglec-8) in the manufacture of a medicament for treating or preventing one or more symptoms of gastritis, enteritis, duodenitis, or gastroenteritis in an individual, wherein the use comprises:

(a) detecting number of mast cells from a first sample obtained from gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual;

(b) detecting number of eosinophils from a second sample obtained from gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual; and

(c) if the first sample has an increased number of mast cells as compared to a mast cell reference and the second sample does not have increased number of eosinophils as compared to an eosinophil reference, an effective amount of the medicament is to be administered to the individual.

2. Use of a composition comprising an antibody that binds to human Siglec-8 in the manufacture of a medicament for treating or preventing one or more symptoms of gastritis, enteritis, duodenitis, or gastroenteritis in an individual, wherein the individual has an increased number of mast cells in at least a portion of the gastric, duodenal, jejunal, ileal, or colonic mucosa as compared to a mast cell reference, and wherein the individual does not have increased number of eosinophils in at least a portion of the gastric, duodenal, jejunal, ileal, or colonic mucosa as compared to an eosinophil reference.

3. The use according to claim 2, wherein a first sample obtained from the gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual has an increased number of mast cells as compared to the mast cell reference, and wherein a second sample obtained from the gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual does not have increased number of eosinophils as compared to the eosinophil reference.

4. The use according to claim 1 or claim 3, wherein the first and the second samples are the same sample, or the first and the second samples are different samples from the same type of tissue.

5. The use according to any one of claims 1, 3, and 4, wherein one or both of the first and second samples is/are from a gastric or duodenal biopsy.

6. The use according to any one of claims 1, 3, and 4, wherein one or both of the first and second samples is/are from an esophago-gastro-duodenoscopy (EGD) with biopsy.

7. The use according to any one of claims 1, 3, and 4-6, wherein the first sample has at least one high-power field (HPF) that has a mast cell count of 20 or more mast cells per HPF.

8. The use according to claim 7, wherein mast cells are detected by immunohistochemical (IHC) staining for tryptase, CD117, or IgE receptor.

9. The use according to any one of claims 1, 3, and 4-8, wherein the second sample has one or more HPFs that each have an eosinophil count of less than 30 eosinophils per HPF.

10. The use according to any one of claims 1, 3, and 4-8, wherein the second sample is obtained from the gastric mucosa of the individual, and wherein the second sample does not have at least five HPFs that each have an eosinophil count of 30 or more eosinophils per HPF.

11. The use according to any one of claims 1, 3, and 4-8, wherein the second sample is obtained from the duodenal mucosa of the individual, and wherein the second sample does not have at least three HPFs that each have an eosinophil count of 30 or more eosinophils per HPF.

12. The use according to any one of claims 1, 3, and 4-11, wherein the number of mast cells in the first sample is detected 45 days or less prior to administration of the composition.

13. The use according to any one of claims 1-12, wherein the individual has, or has been diagnosed with, gastroesophageal reflux disease (GERD).

14. The use according to claim 13, wherein the individual is refractory to treatment with an antacid, H2 blocker, and/or proton pump inhibitor.

15. The use according to any one of claims 1-12, wherein the individual has, or has been diagnosed with, irritable bowel syndrome (IBS).

16. The use according to any one of claims 1-12, wherein the individual has, or has been diagnosed with, functional dyspepsia.

17. The use according to any one of claims 1-12, wherein the individual has had, or has previously been diagnosed with, eosinophilic gastritis, and wherein the individual has one or more symptoms of eosinophilic gastritis without elevated eosinophils.

18. The use according to any one of claims 1-12, wherein the individual has had, or has previously been diagnosed with, eosinophilic gastroenteritis, and wherein the individual has one or more symptoms of eosinophilic gastroenteritis without elevated eosinophils.

19. The use according to any one of claims 1-18, wherein one or both of a number or activity of mast cells in a sample obtained from the gastric, duodenal, jejunal, ileal, or colonic mucosa of the individual are reduced after administration of the composition as compared to a baseline level before administration of the composition.

20. The use according to any one of claims 1-19, wherein, prior to administration of the composition, the individual has failed or is not adequately controlled by one or more standard-of-care treatments for gastritis or gastroenteritis.

21. The use according to claim 20, wherein the one or more standard-of-care treatments for gastritis or gastroenteritis are selected from the group consisting of proton pump inhibitor (PPI) treatment, corticosteroid treatment, and dietary treatment.

22. The use according to any one of claims 1-21, wherein the one or more symptoms of gastritis, duodenitis, enteritis, or gastroenteritis in the individual are reduced after administration of the composition as compared to a baseline level before administration of the composition.

23. The use according to claim 22, wherein the one or more symptoms of gastritis, duodenitis, enteritis, or gastroenteritis in the individual are reduced by at least 60% after administration of the composition as compared to a baseline level before administration of the composition.

24. The use according to any one of claims 1-21, wherein one or more of abdominal pain, nausea, vomiting, loss of appetite, abdominal cramping, fullness before finishing a meal, bloating, diarrhea, and liquid or watery stools in the individual are reduced after administration of the composition as compared to a baseline level before administration of the composition.

25. Use of a composition comprising an antibody that binds to human Siglec-8 in the manufacture of a medicament for treating or preventing one or more symptoms of esophagitis in an individual, wherein the use comprises:

(a) detecting number of mast cells from a first sample obtained from esophageal mucosa of the individual;

(b) detecting number of eosinophils from a second sample obtained from the esophageal mucosa of the individual; and

(c) if the first sample has an increased number of mast cells as compared to a mast cell reference and the second sample does not have increased number of eosinophils as compared to an eosinophil reference, an effective amount of the medicament is to be administered to the individual.

26. Use of a composition comprising an antibody that binds to human Siglec-8 in the manufacture of a medicament for treating or preventing one or more symptoms of esophagitis in an individual, wherein the individual has an increased number of mast cells in at least a portion of the esophageal mucosa as compared to a mast cell reference, and wherein the individual does not have increased number of eosinophils in at least a portion of the esophageal mucosa as compared to an eosinophil reference.

27. The use according to claim 26, wherein a first sample obtained from the esophageal mucosa of the individual has an increased number of mast cells as compared to the mast cell reference, and wherein a second sample obtained from the esophageal mucosa of the individual does not have increased number of eosinophils as compared to the eosinophil reference.

28. The use according to claim 25 or claim 27, wherein the first and the second samples are the same sample, or the first and the second samples are different samples from the same type of tissue.

29. The use according to any one of claims 25, 27, and 28, wherein one or both of the first and second samples is/are from an esophageal biopsy sample.

30. The use according to any one of claims 25, 27, and 28, wherein one or both of the first and second samples is/are from an esophago-gastro-duodenoscopy (EGD) with biopsy.

31. The use according to any one of claims 25, 27, and 28-30, wherein the first sample has at least one high-power field (HPF) with a mast cell count of 10 or more mast cells per HPF.

32. The use according to claim 31, wherein mast cells are detected by immunohistochemical (IHC) staining for tryptase, CD117, or IgE receptor.

33. The use according to any one of claims 25, 27, and 28-32, wherein the second sample has one or more HPFs with an eosinophil count of less than 15 eosinophils per HPF.

34. The use according to any one of claims 25, 27, and 28-32, wherein the second sample does not have an HPF with an eosinophil count of 15 or more eosinophils per HPF.

35. The use according to any one of claims 25-34, wherein the individual has, or has been diagnosed with, gastroesophageal reflux disease (GERD).

36. The use according to claim 35, wherein the individual is refractory to treatment with an antacid, H2 blocker, and/or proton pump inhibitor.

37. The use according to any one of claims 25-36, wherein one or more of a number, activity, or location of mast cells in a sample obtained from the esophageal mucosa of the individual is reduced after administration of the composition as compared to a baseline level before administration of the composition.

38. The use according to any one of claims 25-37, wherein, prior to administration of the composition, the individual has failed or is not adequately controlled by one or more standard-of-care treatments for esophagitis.

39. The use according to any one of claims 25-38, wherein the one or more symptoms of esophagitis in the individual are reduced after administration of the composition as compared to a baseline level before administration of the composition.

40. The use according to claim 39, wherein the one or more symptoms of esophagitis in the individual are reduced by at least 60% after administration of the composition as compared to a baseline level before administration of the composition.

41. The use according to any one of claims 25-38, wherein one or more of heartburn, nausea, dysphagia/difficulty swallowing, vomiting, abdominal pain, cough, food impaction, early satiety, loss of appetite, chest pain, feeding intolerance or refusal, and gastroesophageal reflux in the individual are reduced after administration of the composition as compared to a baseline level before administration of the composition.

42. Use of a composition comprising an antibody that binds to human Siglec-8 in the manufacture of a medicament for treating or preventing one or more symptoms of colitis in an individual, wherein the use comprises:

(a) detecting number of mast cells from a first sample obtained from colonic mucosa of the individual;

(b) detecting number of eosinophils from a second sample obtained from colonic mucosa of the individual; and

(c) if the first sample has an increased number of mast cells as compared to a mast cell reference and the second sample does not have increased number of eosinophils as compared to an eosinophil reference, an effective amount of the medicament is to be administered to the individual.

43. Use of a composition comprising an antibody that binds to human Siglec-8 in the manufacture of a medicament for treating or preventing one or more symptoms of colitis in an individual, wherein the individual has an increased number of mast cells in at least a portion of the colonic mucosa as compared to a mast cell reference, and wherein the individual does not have increased number of eosinophils in at least a portion of the colonic mucosa as compared to an eosinophil reference.

44. The use according to claim 43, wherein a first sample obtained from the colonic mucosa of the individual has an increased number of mast cells as compared to the mast cell reference,

and wherein a second sample obtained from the colonic mucosa of the individual does not have increased number of eosinophils as compared to the eosinophil reference.

45. The use according to claim 42 or claim 44, wherein the first and the second samples are the same sample, or the first and the second samples are different samples from the same type of tissue.

46. The use according to any one of claims 42-45, wherein the colitis is ulcerative colitis.

47. The use according to any one of claims 42 and 44-46, wherein the first sample has at least one high-power field (HPF) with a mast cell count of 30 or more mast cells per HPF.

48. The use according to claim 47, wherein mast cells are detected by immunohistochemical (IHC) staining for tryptase, CD117, or IgE receptor.

49. The use according to any one of claims 42 and 44-48, wherein the second sample has one or more HPFs with an eosinophil count of less than 60 eosinophils per HPF.

50. The use according to any one of claims 42 and 44-48, wherein the second sample does not have an HPF with an eosinophil count of 60 or more eosinophils per HPF.

51. The use according to any one of claims 42 and 44-50, wherein the number of mast cells in the first sample is detected 45 days or less prior to administration of the composition.

52. The use according to any one of claims 42-51, wherein the individual has had, or has previously been diagnosed with, eosinophilic colitis, and wherein the individual has one or more symptoms of eosinophilic colitis without elevated eosinophils.

53. The use according to any one of claims 42-52, wherein one or both of a number or activity of mast cells in a sample obtained from the colonic mucosa of the individual are reduced after administration of the composition as compared to a baseline level before administration of the composition.

54. The use according to any one of claims 42-53, wherein, prior to administration of the composition, the individual has failed or is not adequately controlled by one or more standard-of-care treatments for colitis.

55. The use according to any one of claims 42-54, wherein the one or more symptoms of colitis in the individual are reduced after administration of the composition as compared to a baseline level before administration of the composition.

56. The use according to claim 55, wherein the one or more symptoms of colitis in the individual are reduced by at least 60% after administration of the composition as compared to a baseline level before administration of the composition.

57. The use according to any one of claims 1-56, wherein the composition is to be administered by intravenous infusion.

58. The use according to claim 57, wherein the composition is to be administered by intravenous infusion once a month for 3 or more months.

59. The use according to any one of claims 1-56, wherein the composition is to be administered by subcutaneous injection.

60. The use according to any one of claims 1-56, wherein the composition is to be administered by intravenous infusion at one or more doses comprising between 0.3 mg/kg and 3.0 mg/kg of the antibody.

61. The use according to any one of claims 1-56, wherein the individual is to be administered a first dose comprising 0.3 mg/kg of the antibody, a second dose comprising 1.0 mg/kg of the antibody, and a third dose comprising 3.0 mg/kg of the antibody.

62. The use according to claim 61, wherein the individual is to be administered a first dose comprising 0.3 mg/kg of the antibody on Day 1, a second dose comprising 1.0 mg/kg of the antibody between Day 26 and Day 32, a third dose comprising 3.0 mg/kg of the antibody between Day 54 and Day 60, a fourth dose comprising 3.0 mg/kg of the antibody between Day 82 and Day 88, a fifth dose comprising 3.0 mg/kg of the antibody between Day 110 and Day 116, and a sixth dose comprising 3.0 mg/kg of the antibody between Day 138 and Day 144.

63. The use according to any one of claims 1-62, wherein the antibody comprises a Fc region and N-glycoside-linked carbohydrate chains linked to the Fc region, wherein less than 50% of the N-glycoside-linked carbohydrate chains of the antibody in the composition contain a fucose residue.

64. The use according to claim 63, wherein less than 0.5% of the N-glycoside-linked carbohydrate chains of the antibody in the composition contain a fucose residue.

65. The use according to any one of claims 1-64, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:66.

66. The use according to any one of claims 1-64, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence selected from SEQ ID NOs:67-70; and wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:71.

67. The use according to any one of claims 1-64, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:6; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:16 or 21.

68. The use according to any one of claims 1-64, wherein the antibody comprises:

(a) heavy chain variable region comprising:

(1) an HC-FR1 comprising the amino acid sequence selected from SEQ ID NOs:26-29;

(2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61;

(3) an HC-FR2 comprising the amino acid sequence selected from SEQ ID NOs:31-36;

(4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62;

(5) an HC-FR3 comprising the amino acid sequence selected from SEQ ID NOs:38-43;

(6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and

(7) an HC-FR4 comprising the amino acid sequence selected from SEQ ID NOs:45-46, and

(b) a light chain variable region comprising:

(1) an LC-FR1 comprising the amino acid sequence selected from SEQ ID NOs:48-49;

(2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64;

(3) an LC-FR2 comprising the amino acid sequence selected from SEQ ID NOs:51-53;

(4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65;

(5) an LC-FR3 comprising the amino acid sequence selected from SEQ ID NOs:55-58;

(6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and

(7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60.

69. The use according to any one of claims 1-64, wherein the antibody comprises:

(a) heavy chain variable region comprising:

(1) an HC-FR1 comprising the amino acid sequence of SEQ ID NO:26;

(2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61;

(3) an HC-FR2 comprising the amino acid sequence of SEQ ID NO:34;

(4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62;

(5) an HC-FR3 comprising the amino acid sequence of SEQ ID NO:38;

(6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and

(7) an HC-FR4 comprising the amino acid sequence of SEQ ID NOs:45; and

(b) a light chain variable region comprising:

(1) an LC-FR1 comprising the amino acid sequence of SEQ ID NO:48;

(2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64;

(3) an LC-FR2 comprising the amino acid sequence of SEQ ID NO:51;

(4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65;

(5) an LC-FR3 comprising the amino acid sequence of SEQ ID NO:55;

(6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and

(7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60.

70. The use according to any one of claims 1-64, wherein the antibody comprises:

(a) heavy chain variable region comprising:

(1) an HC-FR1 comprising the amino acid sequence of SEQ ID NO:26;

(2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61;

(3) an HC-FR2 comprising the amino acid sequence of SEQ ID NO:34;

(4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62;

(5) an HC-FR3 comprising the amino acid sequence of SEQ ID NO:38;

(6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and

(7) an HC-FR4 comprising the amino acid sequence of SEQ ID NOs:45; and

(b) a light chain variable region comprising:

(1) an LC-FR1 comprising the amino acid sequence of SEQ ID NO:48;

(2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64;

(3) an LC-FR2 comprising the amino acid sequence of SEQ ID NO:51;

(4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65;

(5) an LC-FR3 comprising the amino acid sequence of SEQ ID NO:58;

(6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and

(7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60.

71. The use according to any one of claims 1-64, wherein the antibody comprises:

a heavy chain variable region comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:88, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:91, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:94; and a light chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:97, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:103;

a heavy chain variable region comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:89, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:92, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:95; and a light chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID

NO:98, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:104; or

a heavy chain variable region comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:90, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:93, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:96; and a light chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:99, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:105.

72. The use according to any one of claims 1-64, wherein the antibody comprises:

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:109;

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:107; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:110; or

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:108; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:111.

73. The use according to any one of claims 65-72, wherein the antibody is a humanized antibody or a chimeric antibody.

74. The use according to any one of claims 65-73, wherein the antibody depletes blood eosinophils and inhibits mast cell activation.

75. The use according to any one of claims 65-74, wherein the antibody comprises a heavy chain Fc region comprising a human IgG Fc region.

76. The use according to claim 75, wherein the human IgG Fc region comprises a human IgG1 Fc region.

77. The use according to claim 76, wherein the human IgG1 Fc region is non-fucosylated.

78. The use according to claim 75, wherein the human IgG Fc region comprises a human IgG4 Fc region.

79. The use according to claim 78, wherein the human IgG4 Fc region comprises the amino acid substitution S228P, wherein the amino acid residues are numbered according to the EU index as in Kabat.

80. The use according to any one of claims 65-72, wherein the antibody has been engineered to improve antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

81. The use according to claim 80, wherein the antibody comprises at least one amino acid substitution in the Fc region that improves ADCC activity.

82. The use according to any one of claims 65-74, wherein at least one or two of the heavy chains of the antibody is non-fucosylated.

83. The use according to any one of claims 1-64, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:75; and a light chain comprising the amino acid sequence selected from SEQ ID NO:76 or 77.

84. The use according to any one of claims 1-83, wherein the antibody is a monoclonal antibody.

85. The use according to any one of claims 1-84, wherein the composition is to be administered in combination with one or more additional therapeutic agent(s) for treating or preventing gastritis, gastroenteritis, or esophagitis.

86. The use according to claim 85, wherein the one or more additional therapeutic agent(s) for treating or preventing gastritis, gastroenteritis, or esophagitis are selected from the group consisting of PPIs, systemic corticosteroids, topical corticosteroids, antihistamines, mast cell stabilizers, H-2 blockers, anti-IgE antibodies, calcineurin inhibitors, immunomodulatory agents, and immunosuppressive agents.

87. The use according to any one of claims 1-86, wherein the individual is a human.

88. The use according to any one of claims 1-87, wherein the composition is a pharmaceutical composition comprising the antibody and a pharmaceutically acceptable carrier.